DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders |
On June16, 2017, Delcath Systems, Inc. (the Company), held
its 2017 Annual Meeting of Stockholders (the Annual
Meeting). Set forth below are the final voting results for
each of the proposals submitted to a vote of the stockholders at
the Annual Meeting.
| 1. |
The nominee for election as a Class II Director, for a three year term, was elected based upon the following vote: |
|
Nominees |
VotesFor |
WithheldAuthority |
BrokerNon-Votes |
|||
|
Harold S. Koplewicz, M.D. |
55,904,342 | 14,184,339 | 39,228,844 |
| 2. |
The proposal to approve, on an advisory basis, the compensation of our named executive officers (say-on-pay), was approved based upon the following votes: |
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||
|
49,229,274 |
16,547,794 |
4,311,613 |
39,228,844 |
| 3. |
The proposal to determine, on an advisory basis, the frequency of the say-on-pay vote (the say-on-frequency vote) received the following votes: |
|
One Year |
Two Years |
Three Years |
Abstentions |
BrokerNon-Votes |
||||
|
52,621,930 |
1,757,728 |
6,986,813 |
8,722,210 |
39,228,844 |
| 4. |
The proposal to ratify the appointment of Grant Thornton, LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017 was approved based upon the following votes: |
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||
|
92,212,969 |
11,900,135 |
5,204,421 |
-0- |
| 5. |
The proposal to approve an amendment to the Companys amended and restated certificate of incorporation to effect a reverse stock split of the Companys common stock, such split to combine a whole number of outstanding shares of our common stock in a range of not less than fifty shares and not more than five hundred shares, in the discretion of the Board, and to grant authorization to the Board to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing, was not approved based upon the following votes, as such proposal received fewer votes in favor than the required majority of the total number of outstanding shares as of the record date required by Delaware law: |
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||
|
70,127,408 |
37,672,937 | 1,517,180 | -0- |
About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
